Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06715267

Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)

The creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care. It will also make it possible to identify the biological samples (histological and molecular) available in routine laboratories, enabling teams of researchers and anatomopathologists to (re)perform certain analyses to re-evaluate diagnoses and search for hitherto unknown molecular prognostic factors.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Myeloproliferative Neoplasm Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases Myeloproliferative Disorders

Age range

0 year–30 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Brest

Brest, 29609, France

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient diagnosed with non-LMC MPN before the age of 30 (PV or TE or MFP or PreMF) according to the 2016 WHO criteria.
  • Signature of the consent form for participation in the FIMBANK project.
  • Agreement to participate in the VYP study.
  • Patient of legal age at the time of inclusion in VYP.
  • Patient affiliated to a social security scheme

Exclusion criteria

  • Refusal to participate by patients of full age
  • Patient under legal protection (guardianship, curatorship, etc.)

Treatment and study plan

Primary outcomes

  1. Describe the epidemiological characteristics of the study population

    Time frame: at enrollment

    Description of MPN subtypes according to age

  2. Describe the mutational landscape of these MPNs

    Time frame: at enrollment

    Rate of mutations JAK2/CALR/MPL

Secondary outcomes

  1. Describe the classical MPN (Myeloproliferative neoplasia) outcomes-1

    Time frame: At 10 years

    Incidence of thrombosis

  2. Describe the classical MPN outcomes-2

    Time frame: At 10 years

    Incidence of myelofibrosis

  3. Describe the classical MPN outcomes-3

    Time frame: At 10 years

    Incidence of MDS/AML

Study contacts

Contact information is provided by the study sponsor or research team.

Jean-Christophe IANOTTO

CONTACT

[email protected]

0298223786 ext. +33

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Official study title

Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications

Acronym: VYP

Important dates

Study start
2023
Primary completion
2038
Study completion
2038
First posted
Dec 4, 2024
Registry last updated
Dec 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.